A1 Refereed original research article in a scientific journal

Lipopolysaccharide-induced non-specific resistance to systemic Escherichia coli infection in mice




AuthorsVuopio-Varkila J, Nurminen M, Pyhälä L, Mäkelä PH

Publication year1988

JournalJournal of Medical Microbiology

Journal name in sourceJournal of medical microbiology

Journal acronymJ Med Microbiol

Volume25

Issue3

First page 197

Last page203

Number of pages7

ISSN0022-2615

DOIhttps://doi.org/10.1099/00222615-25-3-197


Abstract
A high degree of non-specific resistance to a lethal systemic Escherichia coli infection was induced in mice by pretreatment with a small dose (less than 5 micrograms/mouse) of the homologous lipopolysaccharide (LPS) or with heterologous rough-type LPS from E. coli K-12. The route of LPS administration, intraperitoneally or subcutaneously, did not influence the development of resistance, suggesting that a systemic cell activation was responsible for the effect. The enhanced elimination of bacteria was similar to that in mice recovering from a sublethal E. coli infection. In the LPS-treated mice, elimination of the challenge bacteria from the peritoneal cavity and the blood started 3-4 h after challenge whereas, in controls, the bacterial numbers continued to increase until the mice died. The detoxified LPS derivative, monophosphoryl lipid A (MPL), also increased the survival of mice infected with E. coli O18:K1. However, the dose of MPL required for optimal infection resistance was 100-fold greater than that of native, E. coli K-12 LPS, corresponding to the 100-fold reduced toxicity of MPL for mice and rabbits in lethality and pyrogenicity assays.



Last updated on 2024-26-11 at 13:40